261 related articles for article (PubMed ID: 35537412)
1. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.
Hailemichael Y; Johnson DH; Abdel-Wahab N; Foo WC; Bentebibel SE; Daher M; Haymaker C; Wani K; Saberian C; Ogata D; Kim ST; Nurieva R; Lazar AJ; Abu-Sbeih H; Fa'ak F; Mathew A; Wang Y; Falohun A; Trinh V; Zobniw C; Spillson C; Burks JK; Awiwi M; Elsayes K; Soto LS; Melendez BD; Davies MA; Wargo J; Curry J; Yee C; Lizee G; Singh S; Sharma P; Allison JP; Hwu P; Ekmekcioglu S; Diab A
Cancer Cell; 2022 May; 40(5):509-523.e6. PubMed ID: 35537412
[TBL] [Abstract][Full Text] [Related]
2. Probiotics
Wang T; Zheng N; Luo Q; Jiang L; He B; Yuan X; Shen L
Front Immunol; 2019; 10():1235. PubMed ID: 31214189
[TBL] [Abstract][Full Text] [Related]
3. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade.
Luo Y; Shreeder B; Jenkins JW; Shi H; Lamichhane P; Zhou K; Bahr DA; Kurian S; Jones KA; Daum JI; Dutta N; Necela BM; Cannon MJ; Block MS; Knutson KL
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37918918
[TBL] [Abstract][Full Text] [Related]
4. Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration.
Zhou Y; Medik YB; Patel B; Zamler DB; Chen S; Chapman T; Schneider S; Park EM; Babcock RL; Chrisikos TT; Kahn LM; Dyevoich AM; Pineda JE; Wong MC; Mishra AK; Cass SH; Cogdill AP; Johnson DH; Johnson SB; Wani K; Ledesma DA; Hudgens CW; Wang J; Wadud Khan MA; Peterson CB; Joon AY; Peng W; Li HS; Arora R; Tang X; Raso MG; Zhang X; Foo WC; Tetzlaff MT; Diehl GE; Clise-Dwyer K; Whitley EM; Gubin MM; Allison JP; Hwu P; Ajami NJ; Diab A; Wargo JA; Watowich SS
J Exp Med; 2023 Feb; 220(2):. PubMed ID: 36367776
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
6. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
7. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
8. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer.
Chen Y; Sun J; Luo Y; Liu J; Wang X; Feng R; Huang J; Du H; Li Q; Tan J; Ren G; Wang X; Li H
J Transl Med; 2022 Dec; 20(1):615. PubMed ID: 36564797
[TBL] [Abstract][Full Text] [Related]
10. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ
Front Immunol; 2022; 13():872295. PubMed ID: 35634282
[TBL] [Abstract][Full Text] [Related]
12. Faecalibacterium prausnitzii Abrogates Intestinal Toxicity and Promotes Tumor Immunity to Increase the Efficacy of Dual CTLA4 and PD-1 Checkpoint Blockade.
Gao Y; Xu P; Sun D; Jiang Y; Lin XL; Han T; Yu J; Sheng C; Chen H; Hong J; Chen Y; Xiao XY; Fang JY
Cancer Res; 2023 Nov; 83(22):3710-3725. PubMed ID: 37602831
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms underlying immune-related adverse events during checkpoint immunotherapy.
Zhou X; Chen X; Han L; Liu H
Clin Sci (Lond); 2022 May; 136(10):771-785. PubMed ID: 35621125
[TBL] [Abstract][Full Text] [Related]
14. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
15. Abnormal generation of IL-17A represses tumor infiltration of stem-like exhausted CD8
Zhang R; Chen K; Gong C; Wu Z; Xu C; Li XN; Zhao F; Wang D; Cai J; Zhou A; Qu C
BMC Med; 2023 Aug; 21(1):315. PubMed ID: 37605139
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy.
Asrir A; Tardiveau C; Coudert J; Laffont R; Blanchard L; Bellard E; Veerman K; Bettini S; Lafouresse F; Vina E; Tarroux D; Roy S; Girault I; Molinaro I; Martins F; Scoazec JY; Ortega N; Robert C; Girard JP
Cancer Cell; 2022 Mar; 40(3):318-334.e9. PubMed ID: 35120598
[TBL] [Abstract][Full Text] [Related]
17. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
18. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
19. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
Chuah S; Lee J; Song Y; Kim HD; Wasser M; Kaya NA; Bang K; Lee YJ; Jeon SH; Suthen S; A'Azman S; Gien G; Lim CJ; Chua C; Hazirah SN; Lee HK; Lim JQ; Lim TKH; Yeong J; Chen J; Shin EC; Albani S; Zhai W; Yoo C; Liu H; Choo SP; Tai D; Chew V
J Hepatol; 2022 Sep; 77(3):683-694. PubMed ID: 35430299
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-27 Gene Therapy Prevents the Development of Autoimmune Encephalomyelitis but Fails to Attenuate Established Inflammation due to the Expansion of CD11b
Zhu J; Liu JQ; Liu Z; Wu L; Shi M; Zhang J; Davis JP; Bai XF
Front Immunol; 2018; 9():873. PubMed ID: 29740452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
